Immunology / Psoriatic Arthritis
Indication
Psoriatic Arthritis
Assets addressing this indication.
Total attributable cost
$27.1B
$29,742/patient
Drug spend
$12.9B
$14,174/patient
48% of total cost is drugs
All severities · US
18 of 18 assets
Abatacept · Orencia
Protein / enzyme therapeuticApproved
apremilast · Otezla
Small moleculeApproved
bimekizumab · Bimzelx
Monoclonal antibodyApproved
deucravacitinib · Sotyktu
Small moleculeApproved
etanercept · Enbrel
Protein / enzyme therapeuticApproved
HS-10374
Small moleculePhase 3
ixekizumab · Taltz
Monoclonal antibodyApproved
izokibep
Antibody-derived scaffoldPhase 3
LPX-TI641
Small moleculePhase 1
lutikizumab
Monoclonal antibodyPhase 2
netakimab
Monoclonal antibodyApproved
S-4321
Multispecific antibodyPhase 1
secukinumab · Cosentyx
Monoclonal antibodyApproved
si-544
PeptidePhase 1
sonelokimab
Monoclonal antibodyPhase 3
tildrakizumab · Ilumya
Monoclonal antibodyApproved
vunakizumab
Monoclonal antibodyPhase 3
zasocitinib
Small moleculePhase 3